Industry

SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders

Intends to file definitive proxy materials in the coming days BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of … [Read more…]

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free … [Read more…]

HSS Research at EULAR 2025 Congress Shows Routine Test Could Enable Faster, More-Effective Personalized Rheumatoid Arthritis Treatment

BARCELONA, Spain–(BUSINESS WIRE)–Hospital for Special Surgery (HSS) presented new findings at the European Alliance of Associations for Rheumatology (EULAR) Annual Meeting that could help pave the way for more personalized treatment for people with rheumatoid arthritis (RA) by analyzing the cellular composition of synovial fluid inside their joints. RA is a chronic disease characterized by … [Read more…]

EY US Announces Nabiha Saklayen of Cellino as an Entrepreneur Of The Year® 2025 New England Award Winner

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future BOSTON–(BUSINESS WIRE)–#EY–Ernst & Young LLP (EY US) has named Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino, a winner of the Entrepreneur Of The Year® 2025 New England Award. Now celebrating its 40th year, Entrepreneur Of The Year is one of the most … [Read more…]

Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer

FDA Investigational Device Exemption (IDE) Approval enables Presidio’s ULF platform technology to be tested in a pivotal clinical trial in the United States, representing a significant step in bringing this transformational technology to patients who suffer from chronic nociceptive low back pain. SAN MATEO, Calif.–(BUSINESS WIRE)–Presidio Medical, Inc., a global clinical-stage medical device company developing … [Read more…]

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS’ Leadership in Innovative Cancer Therapies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations … [Read more…]

SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients

PARIS–(BUSINESS WIRE)–SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. … [Read more…]

Establishment Labs Hosting Investor Day on June 12

NEW YORK–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and … [Read more…]

Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM

(Securities Code: 4967 JT) *Oasis’s proposals at the EGM had over majority approval, when calculated on the basis of excluding the shares owned by the founding family and its related parties (Majority of Minority, “MoM”) *The Special Resolution (Agenda 1) at the AGM, which called for amendments to Kobayashi Pharma’s Articles of Incorporation, received supermajority … [Read more…]

Manifest MedEx Adds Health-Related Social Services (HRSS) Information to Its Claims and Clinical Data Exchange Network

Social services organizations can now join California’s largest nonprofit health data network to better coordinate whole person care with local hospitals and health plans RIVERSIDE, Calif.–(BUSINESS WIRE)–Manifest MedEx (MX) announced today that health-related social services (HRSS) organizations can now connect and exchange health and HRSS information through its nonprofit health data network to help those … [Read more…]